Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aptivus Labeling Should Note Added Efficacy With Fuzeon, Committee Says

Executive Summary

Labeling for Boehringer Ingelheim's HIV therapy Aptivus should note that tipranavir is most efficacious when used in combination with certain HIV therapies, particularlyFuzeon, members of FDA's Antiviral Drugs Advisory Committee said May 19

You may also be interested in...



Aptivus Clears FDA For HIV; B.I. To Conduct Therapeutic Monitoring Study

Boehringer Ingelheim has agreed to develop a pilot study in therapeutic drug monitoring for its HIV therapy Aptivus (tipranavir)

Aptivus Clears FDA For HIV; B.I. To Conduct Therapeutic Monitoring Study

Boehringer Ingelheim has agreed to develop a pilot study in therapeutic drug monitoring for its HIV therapy Aptivus (tipranavir)

J&J Entry Into HIV Market Will Be Protease Inhibitor In 2006

Johnson & Johnson hopes to have its first approved treatment for HIV on the market by 2006

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel